Payment overview · 2025
General Payments
$452.85
23 reported records · 12 companies
Healthcare provider profile · identity verified
Ian Pelletier, DO
Allopathic & Osteopathic Physicians|Internal Medicine · PILOT KNOB, MO · NPI 1316501000
Verified facts
What the public records show
CMS Open Payments records show Ian Pelletier, DO received $452.85 in general payments during 2025 across 23 reported records.
Novo Nordisk Inc accounted for 27.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Nurtec Odt, Ozempic, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $124.07 | 27.4% | 5 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $73.45 | 16.2% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $72.52 | 16.0% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.77 | 6.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.85 | 5.5% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $24.61 | 5.4% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $20.62 | 4.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.46 | 4.1% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $17.66 | 3.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.09 | 3.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.42 | 3.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.33 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $452.85 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $124.07 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $105.98 | 4 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $73.45 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $72.52 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $24.85 | 1 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $24.61 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $20.62 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.09 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.48 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.33 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $14.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 49 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 38 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
38 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
49 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
69 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 341 | 94 |
| Gabapentin | Gabapentin | 336 | 62 |
| Omeprazole | Omeprazole | 276 | 52 |
| Lisinopril | Lisinopril | 248 | 57 |
| Amlodipine Besylate | Amlodipine Besylate | 233 | 59 |
| Trazodone Hcl | Trazodone Hcl | 180 | 37 |
| Meloxicam | Meloxicam | 178 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 173 | 44 |
| Losartan Potassium | Losartan Potassium | 172 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 168 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 160 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 159 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 150 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 132 | 32 |
| Metformin Hcl | Metformin Hcl | 130 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 125 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 122 | 29 |
| Furosemide | Furosemide | 107 | 23 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 105 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 105 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 104 | 26 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 99 | 23 |
| Potassium Chloride | Potassium Chloride | 99 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 25 |
| Metformin Hcl Er | Metformin Hcl | 97 | 21 |
| Buspirone Hcl | Buspirone Hcl | 96 | 18 |
| Montelukast Sodium | Montelukast Sodium | 94 | 23 |
| Tramadol Hcl | Tramadol Hcl | 94 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 90 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 17 |
| Farxiga | Dapagliflozin Propanediol | 81 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 76 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 76 | 15 |
| Eliquis | Apixaban | 69 | 13 |
| Sertraline Hcl | Sertraline Hcl | 68 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 18 |
| Famotidine | Famotidine | 61 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 19 |
| Spiriva Respimat | Tiotropium Bromide | 61 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | 17 |
| Mirtazapine | Mirtazapine | 59 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 56 | 11 |
| Allopurinol | Allopurinol | 55 | 12 |
| Carvedilol | Carvedilol | 53 | 12 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 53 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | suppressed |
| Trulicity | Dulaglutide | 50 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 50 | 11 |
| Ozempic | Semaglutide | 49 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 46 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 45 | 11 |
| Bumetanide | Bumetanide | 45 | 11 |
| Spironolactone | Spironolactone | 45 | 13 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 44 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 44 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 44 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 41 | suppressed |
| Ibuprofen | Ibuprofen | 41 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 19 |
| Glipizide Er | Glipizide | 40 | suppressed |
| Simvastatin | Simvastatin | 40 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | 12 |
| Propranolol Hcl | Propranolol Hcl | 38 | suppressed |
| Topiramate | Topiramate | 38 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | 12 |
| Aripiprazole | Aripiprazole | 36 | suppressed |
| Glimepiride | Glimepiride | 34 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Prednisone | Prednisone | 33 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Alprazolam | Alprazolam | 31 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 30 | suppressed |
| Verapamil Er | Verapamil Hcl | 30 | suppressed |
| Cilostazol | Cilostazol | 29 | suppressed |
| Jardiance | Empagliflozin | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Roflumilast | Roflumilast | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 20 |
| Ondansetron Odt | Ondansetron | 25 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Lidocaine | Lidocaine | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 22 |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 21 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 14 |
| Brilinta | Ticagrelor | 19 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Novolin R | Insulin Regular, Human | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Pentips Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Tobramycin | Tobramycin | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Dextroamphetamine Sulfate Er | Dextroamphetamine Sulfate | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $452.85 · 23 records | Novo Nordisk Inc | BRIXADI, CAPLYTA, JARDIANCE, MAVYRET, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, Prolastin-C Liquid, REXULTI, Rybelsus, SUBLOCADE, TRELEGY ELLIPTA, VRAYLAR, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error